(UroToday.com) At this year’s European Society of Medical Oncology (ESMO) 2020 Virtual Congress, following two abstracts assessing the role of metformin and local prostate-directed therapy in patients with newly diagnosed, hormone-sensitive metastatic prostate cancer, Dr. Noel Clarke provided an invited discussion of these data.